Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Cetuximab + CFT1946 |
Synonyms | |
Therapy Description | |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
CFT1946 | CFT-1946|CFT 1946 | BRAF Inhibitor 25 | CFT1946 is a bifunctional degradation activation compound (BiDAC) degrader composed of a ligand that targets the BRAF kinase domain linked to a Cereblon ligand, which potentially induces degradation of mutant BRAF and inhibition of tumor growth (Cancer Res 2022;82(12_Suppl):Abstract nr 2158). | |
Cetuximab | Erbitux | IMC-C225 | EGFR Antibody 60 | Erbitux (cetuximab) is a monoclonal antibody directed against EGFR, which inhibits signal transduction and cell proliferation (PMID: 28695301). Erbitux (cetuximab) is FDA approved for use in head and neck squamous cell carcinoma and KRAS wild-type, EGFR positive colorectal cancer (FDA.gov). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05668585 | Phase Ib/II | Cetuximab + CFT1946 CFT1946 + Trametinib CFT1946 | A Study to Characterize the Safety, Tolerability, and Preliminary Efficacy of CFT1946 as Monotherapy and Combination Therapy in Subjects With BRAF V600 Mutant Solid Tumors | Recruiting | USA | FRA | ESP | 0 |